Crystalline forms of genistein

US9012495B2 · kind B2 · utility

Assignee

• AXCENTUA PHARMACEUTICALS AB · SE

Inventors

• Anders Berkenstam · Stockholm, SE
• Stefan Rehnmark · Tullinge, SE
• Michael-Robin Witt
• Keith Lorimer · West Lafayette, US
• Stephen William Watt · Kilmarnock, GB

Key dates

• Filing date: Dec 11, 2009
• Grant date: Apr 21, 2015
• Expiry date: Sep 29, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure relates to new crystalline forms of genistein. The disclosed crystalline forms include crystalline genistein sodium salt dihydrate; crystalline genistein potassium salt dihydrate; crystalline genistein calcium salt; crystalline genistein magnesium salt; crystalline genistein L-lysine salt; crystalline genistein N-methylglucamine salt; crystalline genistein N-ethylglucamine salt; crystalline genistein diethylamine salt; and crystalline genistein monohydrate. The disclosure also relates to the novel genistein salts represented by these crystalline forms. Therapeutic compositions containing at least one of these crystalline forms of genistein and/or a genistein salt and a pharmaceutically acceptable carrier are described. The disclosure also relates to methods of treating cancer comprising the step of administering to a patient in need thereof a therapeutically effective amount of a therapeutic composition containing the compounds of the disclosure, of a crystalline form of genistein, or of a genistein salt.